Update on PML: Lessons from the HIV uninfected and new insights in pathogenesis and treatment

Current HIV/AIDS Reports

Volumn 5, Issue 3, 2008, Pages 112-119

  Hartman, Elizabeth A ^a   Huang, DeRen ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; BETA INTERFERON; BETA1A INTERFERON; CIDOFOVIR; CYCLOSPORIN; CYPROHEPTADINE; CYTARABINE; DACLIZUMAB; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 2; MIRTAZAPINE; NATALIZUMAB; RISPERIDONE; RITUXIMAB; ROSCOVITINE; SEROTONIN 2A ANTAGONIST; SMALL INTERFERING RNA; TOPOTECAN; ZIPRASIDONE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRAIN BIOPSY; BRAIN RADIOGRAPHY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG WITHDRAWAL; HEART TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; IMMUNOSUPPRESSIVE TREATMENT; JC VIRUS; MULTIPLE SCLEROSIS; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; RISK ASSESSMENT; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; BRAIN; IMMUNOLOGY; PATHOPHYSIOLOGY; REVIEW; SERODIAGNOSIS; VIROLOGY;

BRAIN; HIV SERONEGATIVITY; HUMANS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL;

EID: 48949092317     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-008-0018-0     Document Type: Article

References (60)

1. Astrom KE, Mancall EL, Richardson EP Jr: Progressive multifocal leuko-encephalopathy: a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain 1958, 81:93-111.
2. Richardson EP Jr: Progressive multifocal leukoencephalopathy. N Engl J Med 1961, 265:815-823.
3. Langer-Gould A, Atlas SW, Green AJ, et al.: Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005, 353:375-381.
4. Kleinschmidt-DeMasters BK, Tyler KL: Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005, 353:369-374.
5. Van Assche G, Van Ranst M, Sciot R, et al.: Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005, 353:362-368.
6. Calabrese LH, Molloy ES, Huang D, Ransohoff RM: Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum 2007, 56:2116-2128.
7. Lima MA, Koralnik IJ: New features of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy and natalizumab. J Neurovirol 2005, 11(Suppl 3):52-57.
8. Berger JR: Progressive multifocal leukoencephalopathy. Curr Neural Neurosci Rep 2007, 7:461-469.
9. Kitchen A, Miyamoto MM, Mulligan CJ: Utility of DNA viruses for studying human host history: case study of JC virus. Mol Phylogenet Evol 2008, 46:673-682.
10. Zheng HY, Nishimoto Y, Chen Q, et al.: Relationships between BK virus lineages and human populations. Microbes Infect 2007, 9:204-213.
11. Khalili K, White MK, Lublin F, et al.: Reactivation of JC virus and development of PML in patients with multiple sclerosis. Neurology 2007, 68:985-990.
12. Polo C, Perez JL, Mielnichuck A, et al.: Prevalence and patterns of polyomavirus urinary excretion in immunocompetent adults and children. Clin Microbiol Infect 2004, 10:640-644.
13. Drachenberg CB, Hirsch HH, Papadimitriou JC, et al.: Polyomavirus BK versus JC replication and nephropathy in renal transplant recipients: a prospective evaluation. Transplantation 2007, 84:323-330.
14. Aksamit AJ: Review of progressive multifocal leukoencephalopathy and natalizumab. Neurologist 2006, 12:293-298.
15. Garcia-Suarez J, de Miguel D, Krsnik I, et al.: Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies. Am J Hematol 2005, 80:271-281.
16. US Food and Drug Administration: U.S. BL 103705/5230 amendment: RITUXAN® (Rituximab)-Genentech, Inc. Available at http://www.fda.gov/ cder/foi/label/2006/ 103705s5230-s52311bl.pdf. Accessed May 2008.
17. Dorries K, Sbiera S, Drews K, et al.: Association of human polyomavirus JC with peripheral blood of immunoimpaired and healthy individuals. J Neurovirol 2003, 9(Suppl 1):81-87.
18. US Food and Drug Administration: Information for healthcare professionals: rituximab (marketed as Rituxan). Available at http://www.fda.gov/cder/drug/InfoSheets/HCP/ rituximab.pdf. Accessed May 2008.
19. Lee J, Richardson SK, Melhem ER, et al: Progressive multifocal leukoencephalopathy from JC virus in a patient with advanced mycosis fungoides. J Am Acad Dermatol 2007, 57:893-895.
20. Verma S, Cikurel K, Koralnik IJ, et al.: Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera. J Infect Dis 2007, 196:709-711.
21. Boren EJ, Cheema GS, Naguwa SM, et al.: The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J Autoimmun 2008, 30:90-98.
22. National Institute of Neurological Disorders and Stroke: NINDS progressive multifocal leukoencephalopathy information page. Available at http://www.ninds.nih. gov/disorders/pml/pml.htm. Accessed May 2008.
23. Harris HE: Progressive multifocal leucoencephalopathy in a patient with systemic lupus erythematosus treated with rituximab. Rheumatology (Oxford) 2008, 47:224-225.
24. Yamamoto M, Takahashi H, Wakasugi H, et al.: Leukoencephalopathy during administration of etanercept for refractory rheumatoid arthritis. Mod Rheumatol 2007, 17:72-74.
25. Hayashi Y, Kimura A, Kato S, et al.: Progressive multifocal leukoencephalopathy and CD4+ T-lymphocytopenia in a patient with Sjögren syndrome. J Neurol Sci 2008 (Epub 2008 Jan 29).
26. De Raedt S, Lacor P, Michotte A, et al.: Progressive multifocal leukoencephalopathy as first manifestation of sarcoidosis. Clin Neurol Neurosurg 2008, 110:186-189.
27. Shitrit D, Lev N, Bar-Gil-Shitrit A, Kramer MR: Progressive multifocal leukoencephalopathy in transplant recipients. Transpl Int 2005, 17:658-665.
28. van de Beek D, Patel R, Daly RC, et al.: Central nervous system infections in heart transplant recipients. Arch Neurol 2007, 64:1715-1720.
29. Thomas LD, Vilchez RA, White ZS, et al.: A prospective longitudinal study of polyomavirus shedding in lung-transplant recipients. J Infect Dis 2007, 195:442-449.
30. Rossi A, Delbue S, Mazziotti R, et al.: Presence, quantitation and characterization of JC virus in the urine of Italian immunocompetent subjects. J Med Virol 2007, 79:408-412.
31. Kharfan-Dabaja MA, Ayala E, Greene J, et al.: Two cases of progressive multifocal leukoencephalopathy after allogeneic hematopoietic cell transplantation and a review of the literature. Bone Marrow Transplant 2007, 39:101-107.
32. Adelman B, Sandrock A, Panzara MA: Natalizumab and progressive multifocal leukoencephalopathy. N Engl J Med 2005, 353:432-433.
33. Yousry TA, Major EO, Ryschkewitsch C, et al.: Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006, 354:924-933.
34. Stuve O, Marra CM, Jerome KR, et al.: Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006, 59:743-747.
35. Kappos L, Bates D, Hartung HP, et al.: Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 2007, 6:431-441.
36. Ransohoff RM: Natalizumab and PML. Nat Neurosci 2005, 8:1275.
37. Ransohoff RM: "Thinking without thinking" about natalizumab and PML. J Neurol Sci 2007, 259:50-52.
38. Alvarez-Lafuente R, Garcia-Montojo M, De Las Heras V, et al.: Interferon-beta treatment and active replication of the JC virus in relapsing-remitting multiple sclerosis patients. Eur J Neurol 2007, 14:233-236.
39. Delbue S, Guerini FR, Mancuso R, et al.: JC virus viremia in interferon-beta-treated and untreated Italian multiple sclerosis patients and healthy controls. J Neurovirol 2007, 13:73-77.
40. Alvarez-Lafuente R, Garcia-Montojo M, De Las Heras V, et al.: JC virus in cerebrospinal fluid samples of multiple sclerosis patients at the first demyelinating event. Mult Scler 2007, 13:590-595.
41. Inhoff O, Doerries K, Doerries R, et al.: Disseminated cutaneous Kaposi sarcoma and progressive multifocal leukoencephalopathy in a patient with idiopathic CD4+ T lymphocytopenia. Arch Dermatol 2007, 143:673-675.
42. Narula S, LaRosa DF, Kamoun M, et al.: Progressive multifocal leukoencephalopathy in a patient with common variable immunodeficiency and abnormal CD8+ T-cell subset distribution. Ann Allergy Asthma Immunol 2007, 98:483-489.
43. Hecht JH, Glenn OA, Wara DW, Wu YW: JC virus granule cell neuronopathy in a child with CD40 ligand deficiency. Pediatr Neurol 2007, 36:186-189.
44. Takeda S, Yamazaki K, Miyakawa T, et al.: A 64-year-old man presenting MRIs of expansive multiple high intensity areas in the cerebral white matter, cerebellum and brainstem. Neuropathology 2007, 27:403-405.
45. Chang YY, Lan MY, Peng CH, et al.: Progressive multifocal leukoencephalopathy in an immunocompetent Taiwanese patient. J Formas Med Assoc 2007, 106:560-564.
46. Lavagna A, Bergallo M, Daperno M, et al.: Infliximab and the risk of latent viruses reactivation in active Crohn's disease. Inflamm Bowel Dis 2007, 13:896-902.
47. Huang D, Cossoy M, Li M, et al.: Inflammatory progressive multifocal leukoencephalopathy in human immunodeficiency virus-negative patients. Ann Neurol 2007, 62:34-39.
48. Koralnik IJ: Progressive multifocal leukoencephalopathy revisited: has the disease outgrown its name? Ann Neurol 2006, 60:162-173.
49. Owczarczyk K, Hilker R, Brunn A, et al.: Progressive multifocal leucoencephalopathy in a patient with sarcoidosis-successful treatment with cidofovir and mirtazapine. Rheumatology (Oxford) 2007, 46:888-890.
50. Pohlmann C, Hochauf K, Rollig C, et al.: Chlorpromazine combined with cidofovir for treatment of a patient suffering from progressive multifocal leukoencephalopathy. Intervirology 2007, 50:412-417.
51. Viallard JF, Lazaro E, Ellie E, et al.: Improvement of progressive multifocal leukoencephalopathy after cidofovir therapy in a patient with a destructive polyarthritis. Infection 2007, 35:33-36.
52. Co JK, Verma S, Gurjav U, et al.: Interferon-alpha and - beta restrict polyomavirus JC replication in primary human fetal glial cells: implications for progressive multifocal leukoencephalopathy therapy. J Infect Dis 2007, 196:712-718.
53. Tashiro K, Doi S, Moriwaka F, et al.: Progressive multifocal leucoencephalopathy with magnetic resonance imaging verification and therapeutic trials with interferon. J Neurol 1987, 234:427-429.
54. Orba Y, Sunden Y, Suzuki T, et al.: Pharmacological cdk inhibitor R-Roscovitine suppresses JC virus proliferation. Virology 2008, 370:173-183.
55. Radhakrishnan S, Gordon J, Del Valle L, et al.: Intracellular approach for blocking JC virus gene expression by using RNA interference during viral infection. J Virol 2004, 78:7264-7269.
56. Santagata S, Kinney HC: Mechanism of JCV entry into oligodendrocytes. Science 2005, 309:381-382.
57. Focosi D, Kast RE, Maggi F, et al.: 5-HT2a inhibitors for progressive multifocal leukoencephalopathy: old drugs for an old disease. J Infect Dis 2008, 197:328-329.
58. Kast RE, Focosi D, Petrini M, Altschuler EL: Treatment schedules for S-HT2A blocking in progressive multifocal leukoencephalopathy using risperidone or ziprasidone. Bone Marrow Transplant 2007, 39:811-812.
59. Du Pasquier RA, Kuroda MJ, Zheng Y, et al.: A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 2004, 127:1970-1978.
60. Kunschner L, Scott TF: Sustained recovery of progressive multifocal leukoencephalopathy after treatment with IL-2. Neurology 2005, 65:1510.